drugset / Trial / NCT05404919
Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to determine the safety and efficacy of transplanting lungs from hepatitis B virus (HBV) nucleic acid test positive (NAT+) donors into HBV vaccinated HBV surface antibody positive (sAb+) lung transplant candidates, who will then be treated with Hepatitis B Immune Globulin (HBIG) and entecavir, tenofovir disoproxil, or tenofovir alafenamide.
Timeline
- Start
- 2022-09-06
- Primary completion
- 2024-08-01
- Completion
- 2024-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entecavir | Small molecule | — | — |
| Subject | Tenofovir disoproxil fumarate | Small molecule | — | — |
| Subject | tenofovir alafenamide | Small molecule | — | — |
| Background | hepatitis B immune globulin | Protein / enzyme biologic | — | — |